肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

NEJM：Palbociclib联合Fulvestrant治疗晚期乳腺癌

2018-11-15 zhangfan MedSci原创

乳腺癌palbociclibfulvestrant
关注

研究认为，CD4/6抑制剂Palbociclib联合内分泌治疗可显著延长激素受体阳性，人表皮生长因子受体2阴性晚期乳腺癌患者的生存期

细胞周期素依赖性激酶4和6(CDK 4/6)抑制剂Palbociclib联合雌激素受体拮抗剂Fulvestrant治疗可延长激素受体阳性、人表皮生长因子受体2(HER 2)阴性晚期乳腺癌患者的无进展生存期，近日研究人员公布了该疗法对患者总生存期的影响。

先前内分泌疗法治疗后进展或复发的激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌患者参与研究，在Fulvestrant治疗基础上添加palbociclib或安慰剂，研究的主要终点为总生存期。

521名患者参与研究，其中Palbociclib患者的平均生存期为34.9个月，安慰剂组28.0个月（HR=0.81）。410名对先前内分泌治疗敏感的人群中，Palbociclib组患者的平均生存期为39.7个月，安慰剂组29.7个月（HR=0.72）。Palbociclib组平均化疗期为17.6个月，安慰剂组为8.8个月。未发生新的严重不良事件。

研究认为，CD4/6抑制剂Palbociclib联合内分泌治疗可显著延长激素受体阳性，人表皮生长因子受体2阴性晚期乳腺癌患者的生存期。

原始出处：

Nicholas C. Turner et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med， November 15， 2018.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2065861, encodeId=c6672065861fd, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Jan 12 23:31:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051284, encodeId=bbab205128411, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Oct 31 04:31:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657096, encodeId=335d165e0962d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jun 26 20:31:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352861, encodeId=2f863528610e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Sat Nov 17 12:41:24 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Nov 17 00:31:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352795, encodeId=e5b2352e9572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:36:20 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352794, encodeId=59a9352e94aa, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:32:49 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2019-01-12 xqptu

    #fulvestrant#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2065861, encodeId=c6672065861fd, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Jan 12 23:31:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051284, encodeId=bbab205128411, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Oct 31 04:31:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657096, encodeId=335d165e0962d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jun 26 20:31:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352861, encodeId=2f863528610e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Sat Nov 17 12:41:24 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Nov 17 00:31:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352795, encodeId=e5b2352e9572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:36:20 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352794, encodeId=59a9352e94aa, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:32:49 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2019-10-31 xiangyuzhou971

    #EST#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2065861, encodeId=c6672065861fd, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Jan 12 23:31:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051284, encodeId=bbab205128411, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Oct 31 04:31:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657096, encodeId=335d165e0962d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jun 26 20:31:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352861, encodeId=2f863528610e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Sat Nov 17 12:41:24 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Nov 17 00:31:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352795, encodeId=e5b2352e9572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:36:20 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352794, encodeId=59a9352e94aa, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:32:49 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2019-06-26 bsmagic9140

    #TRA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2065861, encodeId=c6672065861fd, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Jan 12 23:31:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051284, encodeId=bbab205128411, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Oct 31 04:31:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657096, encodeId=335d165e0962d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jun 26 20:31:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352861, encodeId=2f863528610e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Sat Nov 17 12:41:24 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Nov 17 00:31:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352795, encodeId=e5b2352e9572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:36:20 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352794, encodeId=59a9352e94aa, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:32:49 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2018-11-17 123fe5b3m29(暂无昵称)

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2065861, encodeId=c6672065861fd, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Jan 12 23:31:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051284, encodeId=bbab205128411, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Oct 31 04:31:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657096, encodeId=335d165e0962d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jun 26 20:31:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352861, encodeId=2f863528610e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Sat Nov 17 12:41:24 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Nov 17 00:31:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352795, encodeId=e5b2352e9572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:36:20 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352794, encodeId=59a9352e94aa, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:32:49 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2018-11-17 ysjykql

    #palbociclib#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2065861, encodeId=c6672065861fd, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Jan 12 23:31:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051284, encodeId=bbab205128411, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Oct 31 04:31:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657096, encodeId=335d165e0962d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jun 26 20:31:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352861, encodeId=2f863528610e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Sat Nov 17 12:41:24 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Nov 17 00:31:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352795, encodeId=e5b2352e9572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:36:20 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352794, encodeId=59a9352e94aa, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:32:49 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2018-11-16 123fe5b3m29(暂无昵称)

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2065861, encodeId=c6672065861fd, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Jan 12 23:31:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051284, encodeId=bbab205128411, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Oct 31 04:31:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657096, encodeId=335d165e0962d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jun 26 20:31:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352861, encodeId=2f863528610e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Sat Nov 17 12:41:24 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372321, encodeId=743f13e232171, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Nov 17 00:31:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352795, encodeId=e5b2352e9572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:36:20 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352794, encodeId=59a9352e94aa, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1f2453890, createdName=123fe5b3m29(暂无昵称), createdTime=Fri Nov 16 22:32:49 CST 2018, time=2018-11-16, status=1, ipAttribution=)]
    2018-11-16 123fe5b3m29(暂无昵称)

    好文章

    0

相关资讯

美例秀秀｜需要医生用心呵护“一生”的乳腺癌

某女，48岁。主诉：左乳癌术后6年余，腹胀1月。2010年3月8日行左乳癌改良根治术 ，术后病理：浸润性小叶癌 T2N0M0，分期IIA期。免疫组化：淋巴结0/15，ER+、PR+、HER-2（ 2+）,未检测FISH以及Ki-67。

美例秀秀｜HER2阳性乳腺癌伴脑转移患者治疗

脑转移是乳腺癌的常见转移部位。HER2阳性乳腺癌属于侵袭性较强的疾病，易发生脑转移。患者出现脑转移后，不应放弃，更需要积极的抗肿瘤。以下将介绍1例HER2阳性早期乳腺癌患者，复发后出现脑转移。在晚期治疗阶段，持续抑制HER2，即使在抗HER2治疗失败后，也继续抗HER2治疗，目前患者取得较好的疾病控制，疗效维持PR达到5年，并继续获益。

别睡了！睡眠过多！乳腺癌风险增加20%！

又到了出了被窝都是远方，起床都是背井离乡的冬日了，可是如果我说多睡增加乳腺癌风险，那你还敢赖床吗？这可不是危言耸听，而是来自两项实实在在的大型研究。结果表明：早晨状态更好的女性患乳腺癌的风险可能会降低，而多睡则会增加乳腺癌风险。

APESM：苏州医工所在乳腺断层摄影研究中取得进展

在我国，乳腺癌是女性发病率最高的癌症，在所有女性癌症中占比高达16.51%（参见国家癌症中心发布的《2018年全国最新癌症报告》）。近年来，我国乳腺癌发病率已经逐年升高，且呈现年轻化趋势。

HER2过表达——乳腺癌诊治必须扭住的“牛鼻子”

某女，61岁女性。2018年6月7日入我科治疗。2014年8月因右乳肿物于外院行右乳腺癌改良根治术。术后病理：右乳腺浸润性导管癌Ⅲ级，肿瘤大小2.0*1.5*1.0cm，切缘未见肿瘤，同侧腋窝淋巴结可见癌转移（1/13）, ER(-), PR(-), HER2(+++), ki-67 ：30%，P53（-）。分期：pT1N1M0 IIA期，St-Gallen 分子分型为HER2过表达型.治疗经过：

BioRxiv：早起的女人，患乳腺癌风险更低？

近日，一项大型研究结果显示：早起的女性可能会降低患乳腺癌的风险。